EP Patent

EP3042659A1 — Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydroisoindol-2-yl)-piperidine-2,6-dione

Assigned to Celgene Corp · Expires 2016-07-13 · 10y expired

What this patent protects

A polymorphic form of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione is disclosed. Compositions comprising the polymorphic form, methods of making the polymorphic form and methods of its use are also disclosed.

USPTO Abstract

A polymorphic form of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione is disclosed. Compositions comprising the polymorphic form, methods of making the polymorphic form and methods of its use are also disclosed.

Drugs covered by this patent

Patent Metadata

Patent number
EP3042659A1
Jurisdiction
EP
Classification
—
Expires
2016-07-13
Drug substance claim
No
Drug product claim
No
Assignee
Celgene Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.